Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Cannabis Pharmaceuticals Market?

The market size for cannabis pharmaceuticals has seen significant expansions in the past few years. From a worth of $6.03 billion in 2024, it is expected to blossom to $9.43 billion in 2025, with a projected compound annual growth rate (CAGR) of 56.4%. Factors contributing to the growth in the historic period include increased legalization of medicinal cannabis, heightened awareness of the therapeutic benefits of cannabinoids, a rise in chronic and neurological conditions, positive changes in regulatory frameworks, amplified investments by pharmaceutical companies, and shifting attitudes toward the use of cannabis in medical treatments.

In the coming years, the cannabis pharmaceuticals market size is predicted to experience significant expansion, reaching $55.53 billion in 2029, and exhibiting a compound annual growth rate (CAGR) of 55.8%. This substantial growth during the anticipated period is due to several factors such as the increasing approval of regulations, enhanced understanding of the advantages of medical cannabis, its increasing use in managing pain and neurological issues, the growth in chronic disease prevalence, the innovation of drug delivery systems, and the implantation of favorable reimbursement policies. The estimated period will also see major trends like advancements in the extraction technology for cannabinoids, the development of targeted drug delivery systems, the utilization of synthetic cannabinoid formulations, better methodologies for clinical trials, and the use of artificial intelligence in drug discovery.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What Are The Primary Factors Supporting The Cannabis Pharmaceuticals Market Expansion?

The increase in epilepsy cases is projected to spur the growth of the cannabis pharmaceuticals industry. Epilepsy, a neurological condition marked by repeated, unprovoked seizures due to irregular brain electrical activity is on the rise. The increased number of epilepsy cases can be owed to better diagnosis, increased consciousness, improved reporting, and potential environmental, genetic, and lifestyle factors. Cannabis pharmaceuticals, utilizing cannabinoids like CBD, have demonstrated potential in managing epilepsy by reducing the scale and intensity of seizures in patients unresponsive to standard anti-epileptic medicines. For example, in April 2022, the Belgium-based non-profit European Brain Council revealed that over 600 neurological diseases and nearly 300 psychiatric conditions plague millions worldwide, including 65 million epileptics. Additionally, in July 2024, according to Canada’s Alzheimer Society, on January 1, 2025, an estimated 771,939 Canadians will suffer from dementia, a number projected to approach one million by 2030. As a result, the escalating epilepsy cases are propelling the expansion of the cannabis pharmaceuticals industry.

Which Segments Define The Structure Of The Cannabis Pharmaceuticals Market?

The cannabis pharmaceuticalsmarket covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions

3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management

4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids

What Strategic Shifts And Innovations Are Influencing The Cannabis Pharmaceuticals Market?

Key corporations in the cannabis pharmaceutical sector are prioritizing the creation of ground-breaking products such as advanced medical cannabis formulations. These are aimed at catering to a variety of health issues and enhancing patient results. Advanced medical cannabis formulas are custom-made cannabis-centric products, meticulously designed for therapeutic use, encompassing accurate doses of cannabinoids like THC and CBD. For example, in April 2024, Switzerland’s pharmaceutical firm, Canexis Pharma AG, was awarded manufacturing and narcotics certifications by Swissmedic, pertaining to cannabis pharmaceuticals. Such endorsements allow the firm to manufacture top-quality medicinal ingredients originating from CBD and THC. This progress situates Canexis in a position to satisfy the burgeoning requirement for medical cannabis, both domestically and internationally. By earning these accreditations, the firm showcases its adherence to rigorous regulatory norms, boosting its trustworthiness and potential to make significant contributions to the swiftly expanding medical cannabis sector.

Who Are The Primary Market Leaders In The Cannabis Pharmaceuticals Market?

Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte’s Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

What Regional Factors Are Accelerating Growth In The Cannabis Pharmaceuticals Market?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Browse Through More Reports Similar to the Global Cannabis Pharmaceuticals Market 2025, By The Business Research Company

Cannabis Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-products-global-market-report

Cannabis Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

Cannabis Cultivation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-cultivation-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model